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ABSTRACT
The CRISPR–Cas9 system is a powerful genome-
editing tool useful in a variety of biotechnology and
biomedical applications. Here we developed a syn-
thetic RNA-based, microRNA (miRNA)-responsive
CRISPR–Cas9 system (miR-Cas9 switch) in which
the genome editing activity of Cas9 can be mod-
ulated through endogenous miRNA signatures in
mammalian cells. We created miR-Cas9 switches by
using a miRNA-complementary sequence in the 5′-
UTR of mRNA encoding Streptococcus pyogenes
Cas9. The miR-21-Cas9 or miR-302-Cas9 switches
selectively and efficiently responded to miR-21-5p in
HeLa cells or miR-302a-5p in human induced pluripo-
tent stem cells, and post-transcriptionally attenuated
the Cas9 activity only in the target cells. Moreover,
the miR-Cas9 switches could differentially control
the genome editing by sensing endogenous miRNA
activities within a heterogeneous cell population. Our
miR-Cas9 switch system provides a promising frame-
work for cell-type selective genome editing and cell
engineering based on intracellular miRNA informa-
tion.
INTRODUCTION
The bacterial and archaeal clustered regularly inter-
spaced short palindromic repeats (CRISPR) and CRISPR-
associated (Cas) system provided a powerful genome edit-
ing tool for a variety of biotechnology and biomedical
applications (1,2). The engineered CRISPR–Cas9 system
derived from Streptococcus pyogenes contains two com-
ponents: the Cas9 endonuclease and a single guide RNA
(sgRNA), which itself is a fusion of a designable CRISPR
RNA (crRNA) and an universal trans-activating CRISPR
RNA (tracrRNA). The Cas9 complex is recruited to a tar-
get DNA sequence by the sgRNA, forming an RNA–DNA
hybrid. Subsequently, the endonuclease activity of Cas9 cre-
ates a DNA double strand break (DSB) at the target site
and triggers a hostDNA repair pathways to induce genomic
alterations. To introduce the system into mammalian cells,
several delivery approaches for Cas9 and the sgRNA have
been tested, including viral vectors, plasmid DNAs, syn-
thetic RNAs, and ribonucleoproteins (RNPs) (3–5). DNA-
based delivery systems may induce unwanted side effects.
For example, gene therapy using virus vectors may inte-
grate the transgene into host genomic regions randomly,
and induce oncogenesis in some cases (6). It has also been
reported that plasmid delivery of the CRISPR–Cas9 sys-
tem may cause genomic integration of the DNA fragment
derived from the plasmid at off-target sites (7). Detection
of the inserted DNA fragment at off-target sites is diffi-
cult, and the insertion might cause problems to host cells.
In contrast, RNA-based delivery approaches are proposed
to be safer than DNA-based delivery, since the limited ex-
pression window for RNA could reduce the risk of off-
target mutagenesis while also avoiding the possibility of
random genomic integration (3,4,8). Additionally, by using
synthetic genetic circuits delivered by modified mRNAs (8),
one may be able to control Cas9 protein expression post-
transcriptionally by sensing intracellular signals. However,
the post-transcriptional regulation of Cas9 activity by em-
ploying synthetic mRNA has remained a challenge.
Multicellular organisms consist of various cell types,
hence cell type-specific genome editing will be an important
tool for restricting genetic modifications to target cells and
regulating the cell-fate within sub-populations in vitro and
in vivo. The ideal system is one that modifies the target cells
without affecting other cell types. In order to regulate the
endonuclease activity of Cas9, several methods have been
reported, including optogenetic or small molecule/protein-
inducible systems (9–11), a tissue-specific promoter system
(12), and transcriptional regulatory circuits using split-Cas9
(13). However, these reports have predominantly usedDNA
delivery approaches. And cell type-selective genome edit-
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ing in a heterogeneous cell population has not been imple-
mented previously.
MicroRNAs (miRNA) are small non-coding RNA that
regulates gene expression through translational repression
and/or mRNA degradation. The miRNA activities differ
in each cell type and can therefore be used as a signature
for a given target cell (14). We have previously reported a
miRNA-responsive, synthetic mRNA (miRNA switch) that
enables the detection and purification of target cells based
on endogenousmiRNA activities. By inserting a copy of the
anti-sense sequence for the target miRNA (anti-miRNA)
into the 5′-UTR of the mRNAs, the switch allows for sen-
sitive detection of the target miRNA upon hybridization
and subsequent post-transcriptional repression of a down-
stream protein (15). Additionally, these miRNA switches
function with RNA delivery to avoid random genome in-
tegration and purify target cell populations with high effi-
ciency and selectivity (15,16).
We hypothesized that a combination of miRNA switch
technology with the CRISPR–Cas9 system (i.e. miRNA-
responsive Cas9 system:miR-Cas9 switch) would enable the
regulation of genome engineering in a miRNA-dependent
manner (Figure 1). In the present study, we newly designed
amiR-Cas9 switch that controlledCas9 activity based on an
endogenous miRNA expressed in target human cells. Cas9
protein was translated from a miR-Cas9 switch in the ab-
sence of the target miRNA (ON-state), but was repressed
in its presence (OFF-state). We used this system to atten-
uate Cas9 activity in HeLa cells, human induced pluripo-
tent stem cells (hiPSCs), iPSC-derived differentiated neu-
ronal cells. In turn, we demonstrate that cell-type selective
genome editing can be achieved in heterogeneous cell pop-
ulations.
MATERIALS AND METHODS
Preparation of template DNA for IVT (in vitro transcription)
pAM-L7Ae was prepared according to the same method
as pAM-tagBFP described in a previous report (15). The
PCR product of tagBFP was inserted into modified pUC19
vector at a multi-cloning site to obtain pA9-tagBFP. The
original sources of the genes and plasmid sequences are de-
scribed in Supplementary Table S6. For the preparation of
Cas9 mRNA, L7Ae mRNA and BFP mRNA templates,
a 5′-UTR without miRNA target sequences (control 5′-
UTR) and a 3′-UTRwere synthesized by hybridizing oligo-
DNAs (oligo-DNAs lists are shown in Supplementary Ta-
ble S1) followed by elongation; (94◦C for 2 min, 13 cy-
cles of 98◦C for 10 s and 68◦C for 10 s, and hold at 4◦C).
Cas9, L7Ae and BFP protein-coding regions were ampli-
fied by PCR with the appropriate primers (Supplementary
Table S4) from pHL-EF1a-SphcCas9-iC-A (Addgene, Plas-
mid #60599), pAM-L7Ae and pA9-tagBFP, respectively.
The plasmid DNA was removed following PCR by Dpn
I treatment. All PCR products were purified by MinElute
PCR purification kit (QIAGEN). The PCR products were
then fused to construct a full DNA template for IVT via
an additional PCR reaction. We conducted gel extraction
when non-specific bands appeared.
For the sgRNA template, a modified protocol (17) was
used. Briefly, a forward primer containing the T7 promoter
Figure 1. Schematic illustrations of the miR-Cas9 switch. (A) Design
of miRNA-responsive Cas9 mRNA (miR-Cas9 switch). The synthetic
mRNA contains an anti-reverse cap analog (yellow), miRNA target site
(orange), Cas9 encoding sequence (cyan), and 120 nucleotide poly(A) tail.
The miRNA target site is completely complementary to the miRNA of in-
terest. (B) Overview of the miR-Cas9 switch system. The miR-Cas9 switch
and sgRNA are introduced to cells by RNA transfection. Cas9 protein ex-
pressed from the mRNA forms a Cas9–sgRNA complex and digests the
DNA in the case of no miRNA activity (ON, left). In contrast, in the case
of highmiRNAactivity, interaction between themiRNAandCas9mRNA
reduces Cas9 expression (OFF, right).
sequence immediately followed by the gene-targeting se-
quence and a reverse primer encoding the remainder of the
sgRNA sequence were used.
The complete list of combined primers and template for
the PCR reactions is shown in Supplementary Table S4.
Cas9-, L7Ae- and BFP-mRNAs and sgRNA synthesis and
purification
Cas9 mRNAs (with or without miRNA target sequences
and with kink-turn motif), L7Ae mRNAs (with or
without miRNA target sequences) and BFP mRNA
(without miRNA target sequences) were prepared by
using a MEGAscript kit (Ambion). In order to re-
duce the interferon response caused by long RNA,
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pseudouridine-5′-triphosphate and 5-methylcytidine-5′-
triphosphate (TriLink Bio Technologies) were used instead
of natural rUTP and rCTP, respectively (18). Guanosine-5′-
triphosphate was 5-fold diluted with an Anti Reverse Cap
Analog (TriLink Bio Technologies) before the IVT reaction.
The sgRNA was constructed using a MEGAshortscript kit
(Ambion) according to the instruction manual. Because
sgRNA with modified bases may cause downregulation
of Cas9 activity, natural rNTPs were used for preparing
sgRNA. The template DNA was degraded by TURBO
DNase (Ambion), and the mRNAs and sgRNA were
purified using a FavorPrep Blood/Cultured Cells total
RNA extraction column (Favorgen Biotech) incubated
with Antarctic Phosphatase (New England Biolabs) at
37◦C for 30 min and then purified again using an RNeasy
MinElute Cleanup Kit (QIAGEN). For further purifica-
tion, sgRNA was electrophoresed, extracted from gel (10%
polyacrylamide gel, 8.3 M urea), and ethanol-precipitated.
Cell culture
The heterozygously targeted AAVS1-CAG::GFP human
iPSCs 317-12 line (hiPSC-EGFP) (19) was maintained
in StemFit (Ajinomoto) on laminin-511 E8 (iMatrix-511,
nippi). HeLa-EGFP cells were cultured in DMEM High
Glucose (nacalai tesque) supplemented with 10% FBS
(JBS) and Hygromycin B (50 g/ml). Normal HeLa cells
were cultured in DMEM High Glucose (nacalai tesque)
supplemented with 10% FBS (JBS). All cell lines were cul-
tured at 37◦C with 5% CO2.
RNA transfection
For all assays, HeLa-EGFP and normal HeLa cells were
seeded in uncoated 24-well plates, while iPS-EGFP cells
were seeded in laminin-coated 24-well plates (all cells were
seeded at a density of 5 × 104 cells/well). Appropriate syn-
thetic RNAs were transfected into the cells using a Stem-
fect RNA transfection kit according to the manufacturer’s
protocol (Stemgent). The medium was changed 4 h after
transfection. Cells were cultured for 24 h (Evaluation of
transfection efficiency, Evaluation of gene expression level
and Evaluation of Cas9 protein expression level), 48 h (Cell
killing assay by targetingAlu1 element) or 72 h (T7E1 assay,
Cas9 activity assay, Co-culture assay for cell-type-selective
genome editing and Construction of miR-Cas9-ON switch)
after transfection. Before analysis, cultured cells were cap-
tured by an IX81 microscope with output to a CCD camera
(Olympus).
Cas9 activity assay
100 ng Cas9 mRNA, 300 ng sgRNA and 5 pmol miRNA
inhibitor/negative control (ThermoFisher, optional) were
used. MiRNA negative control (referred to as nega-
tive miRNA inhibitor henceforth) was provided by Ther-
moFisher as mirVana™ miRNA Mimic Negative Control
and is a random sequence Anti-miRmolecule that has been
extensively tested in human cell lines and tissues and vali-
dated to not produce identifiable effects on known miRNA
function. At 72 h after RNA transfection of miR-Cas9
switch, cells were washed with PBS. HeLa-EGFP cells were
treated with 100 l 0.25% trypsin–EDTA, incubated at
37◦C with 5% CO2 for 5 min, and then 100 l cultured
medium was added. iPS-EGFP cells were treated with 200
l Accumax (Funakoshi) and incubated at 37◦C with 5%
CO2 for 10 min. These cells were collected into 1.5 ml tubes,
stained with SYTOX Red dead-cell stain (ThermoFisher),
and incubated at room temperature for 15 min with pro-
tection from ambient light. Samples were analyzed on an
Aria-II (BD Biosciences), Accuri C6 (BD Biosciences) or a
LSRFortessa (BD Biosciences) flow cytometer.
From histogram or dot plots (SSC-A versus EGFP), we
gated for EGFP negative and positive populations, which
correspond to successful or non-successful knock-out of
EGFP gene by Cas9, respectively.
Co-culture assay for cell-type-selective genome editing
Before collection, cells were washed with PBS. Cells were
treated with 200 l Accumax (Funakoshi) and incubated
at 37◦C with 5% CO2 for 10 min. These cells were col-
lected into 1.5 ml tubes and centrifuged at 1000 rpm and
room temperature for 5 min. After supernatant was dis-
carded, 50 l PBS + PI (BD Biosciences) mixture and 2.5
l Alexa Fluor® 647 mouse anti-human TRA-1-60 anti-
gen (BD Biosciences) were added and incubated at room
temperature for 20 min with protection from ambient light.
After incubation, 1 ml PBS was added and centrifuged at
1000 rpm and room temperature for 5 min (2 times). After
adding 400 l PBS, the samples were analyzed on an LSR
(BD Biosciences) flow cytometer.
For immunostaining, transfected cells were treated with
the following protocol. Cells were washed with PBS (2
times) and treated with 200l BDCytoxfix™ fixation buffer
(BD Biosciences) for 10 min at room temperature. After 10
min, buffer was removed, and cells were washed (2 times).
Cells were stained with 200 l antibody (Alexa Fluor® 647
mouse anti-human TRA-1-60 antigen (BD Biosciences))
diluted in PBS (5 l antibody/200 l PBS) for 1 h at
room temperature with protection from ambient light. Af-
ter staining, cells were washed with PBS (2 times). Upon
adding 500 l PBS, cells were captured by the IX81 micro-
scope with output to the CCD camera (Olympus).
Construction of miR-Cas9-ON switch
Harvesting and analysis were done as in Cas9 activity assay
above. Briefly, sample cells were collected 72 h after RNA
transfection and stained with SYTOX Red dead-cell stain.
These samples were analyzed on an Accuri flow cytometer.
Flow cytometry
An Accuri flow cytometer with FL1 (533/30 nm) and FL4
(675/25 nm) filters was used. EGFP and annexin V, Alexa
Fluor 488 conjugate were detected with FL1, and SYTOX
Red dead-cell stain was detected with FL4. EGFP, SYTOX
Red dead-cell stain, PI and Alexa Fluor® 647 mouse anti-
human TRA-1-60 antigen were detected with a blue laser
(488 nm) and FITC filter (530/30 nm), a red laser (633
nm) and APC filter (660/20 nm), a blue laser and PE filter
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(575/25 nm), and a red laser and APC filter, respectively,
using Aria-II or LSR flow cytometers.
Statistical analysis
Student’s t test or Welch’s t test (Supplementary Figure S3
only) were used for the statistical analysis. The levels of sig-
nificance are denoted as *P < 0.05, **P < 0.01, ***P <
0.001, n.s., not significant. Student’s t test andWelch’s t test
were performed using Excel (Microsoft).
RESULTS
Construction of miR-Cas9 switch
We first constructed Cas9 mRNA that contains a miRNA-
responsive anti-sense sequence (anti-miR) positioned
within the 5′-UTR (Figure 1A). When the miRNA is
inactive in cells, Cas9 protein will be produced from Cas9
mRNA and result in endonuclease activity that cleaves a
target DNA sequence (Figure 1B, left). In contrast, when
the miRNA is active in the cell, the expression from the
Cas9 mRNA will be repressed through the interaction
between the anti-miR region of the Cas9 mRNA and the
endogenous miRNA. This interaction will cause post-
transcriptional repression of Cas9 expression, reducing the
level of DNA cleavage (Figure 1B, right). To evaluate the
activity of Cas9, we employed sgRNAGFP, which cleaves an
enhanced green fluorescent protein (EGFP) reporter gene
integrated into the host cell’s genome, and quantified Cas9
activity by assessing the loss of the EGFP fluorescence
intensity (20).
We investigated whether the designed miR-Cas9 switch
could control Cas9 endonuclease activity in HeLa-EGFP
cells that constitutively express EGFP (Figure 2). In this
study, we focused on miR-21-5p (miR-21) and miR-302a-
5p (miR-302). MiR-21 is highly expressed in many cancer
cells including HeLa cells and regulates tumor suppressor
genes associated with proliferation, apoptosis and invasion
(e.g. PTEN, PDCD4, BCL-2) (21,22). MiR-302 is predomi-
nantly expressed in human pluripotent stem cells including
hiPSCs (15,23) and regulates pluripotency, proliferation,
and cell cycle-related genes (e.g. MBD2, AKT1, CDK4).
Indeed, we confirmed that miR-21 and miR-302 are highly
expressed in HeLa cells and hiPSCs, respectively (Supple-
mentary Figure S1). Thus, we chose miR-21 and miR-302
as target miRNAs to conduct HeLa cell- or hiPSC-specific
genome editing.
We prepared three Cas9 mRNAs, control Cas9 mRNA
without anti-miR sequence, miR-21-responsive Cas9
mRNA (miR-21-Cas9 switch), and miR-302-responsive
Cas9 mRNA (miR-302-Cas9 switch). We expected that
Cas9 expression from the miR-21-Cas9 switch would be
repressed in the presence of endogenous miR-21, resulting
in a loss of Cas9 activity in HeLa cells. We co-transfected
either control Cas9 mRNA or miR-21-Cas9 switch and
sgRNAGFP into HeLa-EGFP cells. Three days after trans-
fection, we analyzed the EGFP intensity by fluorescence
microscopy and flow cytometry. These analyses showed
a decrease in EGFP expression in control Cas9 mRNA-
transfected cells compared with untreated cells, indicating
successful knock-out of the EGFP gene by Cas9 mRNA
and sgRNAGFP (Figure 2A and B). In contrast, there was
no significant loss in EGFP expression in miR-21-Cas9
switch-transfected cells. The fluorescence intensity was
similar to that of untreated cells or cells transfected with
Cas9 mRNA and negative control sgRNADMD, which
targets an unrelated genomic region (human Dystrophin
gene, DMD) (24) (Figure 2A and B). To investigate the
selectivity of our miR-Cas9 switch, we also transfected
the miR-302-Cas9 switch, which was designed to re-
spond to miR-302, a miRNA not expressed in HeLa cells
(Supplementary Figure S1B). We observed a decrease
in EGFP intensity to a level similar to positive control
Cas9 mRNA, suggesting that the insertion of unrelated
miRNA-responsive sequences in the 5′UTR region of Cas9
mRNA does not affect its translation efficiency (Figure
2A and B). We further quantified Cas9 activities based
on the fluorescence intensity obtained by flow cytometry
analysis (Figure 2C). We observed a decrease in EGFP
intensity in control Cas9 mRNA and miR-302-Cas9
switch transfected cells (∼50% of the cell population was
EGFP-low), but EGFP intensity from miR-21-Cas9 switch
transfected-cells was again similar to that of untreated
cells or cells transfected with Cas9 mRNA and negative
control sgRNADMD (∼90% of cells were EGFP-positive).
In addition, we confirmed Cas9 protein expression levels
from each mRNA by capillary-based immunodetection.
We detected Cas9 protein produced from Cas9 mRNA and
miR-302-Cas9 switch but not from miR-21-Cas9 switch
(Supplementary Figure S2). These results indicate that
Cas9 expression from miR-21-Cas9 switch was regulated
by endogenous miR-21 in HeLa cells.
To confirm whether endogenous miR-21 is responsible
for controlling Cas9 activity in HeLa-EGFP cells, the miR-
21-Cas9 switch was co-transfected with either miR-21 in-
hibitor or miRNA inhibitor unrelated to miR-21 (negative
inhibitor). We observed a decrease in EGFP intensity (i.e.
increase of Cas9 activity) in the case of co-transfection with
miR-21-Cas9 switch and miR-21 inhibitor, but not with
miR-21-Cas9 switch and negative inhibitor (Figure 2D), in-
dicating the rescue of Cas9 activity by inhibiting endoge-
nous miR-21 activity. These results indicated that endoge-
nous miR-21 in HeLa-EGFP cells is indispensable in the
repression of Cas9 protein expression from the miR-21-
Cas9 switch. Thus, we succeeded in constructing a synthetic
RNA-delivered, miRNA-responsive Cas9 system in mam-
malian cells.
miR-Cas9 switch that targets endogenous Alu1 element
Next, we investigated the versatility of our switch by tar-
geting a different region of the endogenous genome. We fo-
cused on the Alu1 element, the most common short inter-
spaced element (SINE) in humans, distributed as thousands
of copies throughout the human genome (25). We hypoth-
esized that the cleavage of Alu1 regions by Cas9 would in-
duce genotoxic stress resulting in cell death (Supplementary
Figure S3A).We designed sgRNA targeting theAlu1 region
(sgRNAAlu1), which exists in >200 000 sites in the human
genome (219 114 sites in hg19), and transfected sgRNAAlu1
and Cas9 mRNA in HeLa cells. As expected, the number
of dead cells increased in the case of treatment with con-
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Figure 2. Regulation of Cas9 activity in HeLa cells by miR-21-Cas9 switch. (A) Representative phase contrast and fluorescent microscopic images at 72
h after RNA transfection. Scale bar represents 200 m. (B) Representative flow cytometry histograms of EGFP expression. x- and y-axes indicate EGFP
intensity and % of max, respectively. (C) Quantification of Cas9 activity from (B). The percentage of EGFP negative cells was defined as Cas9 activity. Cas9
activity was reduced in miR-21-responsive Cas9mRNA. (D) Verification of endogenous miR-21-dependent Cas9 silencing by using miR-21 inhibitor. The
miR-21 inhibitor rescued Cas9 activity in miR-21-responsive Cas9 mRNA, whereas a negative miRNA inhibitor did not. For the negative control, cells
were transfected with Cas9 mRNA and a non-targeting sgRNA (sgRNADMD). Error bars indicate the mean ± SD (n = 3).
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trol Cas9 mRNA and sgRNAAlu1, whereas cells untreated
or treated with controlCas9mRNAand sgRNADMD main-
tained a normal cell phenotype. Importantly, cells treated
with miR-21-Cas9 switch and sgRNAAlu1 did not increase
the number of dead cells, indicating that our miR-Cas9
switch can target endogenous genomic sequences and se-
lectively control cell death signals (Supplementary Figure
S3B–D).
miR-302-Cas9 switch modulates genome editing in human
iPS cells
To further test our miR-Cas9 switch in different cell types,
we next chose a human iPS cell line (201B7) that contains a
single copy of the EGFP gene at the AAVS1 locus, which
is often considered a safe-harbor for transgene targeting
(hiPSC-EGFP) (19). We used the miR-302-Cas9 switch to
selectively repress Cas9 activity in hiPSCs. Although the
miR-302-Cas9 switch did not affect the Cas9 activity in
HeLa cells (Figure 2A–C), we observed a repression of Cas9
activity (recovery of EGFP intensity) in hiPSCs transfected
with miR-302-Cas9 switch and negative miRNA inhibitor,
and de-repression of Cas9 activity in hiPSCs transfected
withmiR-302-Cas9 switch andmiR-302 inhibitor. These re-
sults suggest that the suppression is dependent on endoge-
nous miR-302 in hiPSCs (Supplementary Figure S4A).
We also performed T7E1 assays to investigate whether
the change in EGFP intensity observed in the flow cytome-
try analysis was caused by mutations in the target EGFP
gene due to the Cas9 activity. Treating the DNA prod-
ucts from genomic PCR with T7 Endonuclease I, we ob-
served the target cleaved bands in cells transfected with
Cas9 mRNA, or with miR-302-Cas9 switch and miR-302
inhibitor (Supplementary Figure S5). However, we did not
observe these bands in cells treated with miR-302-Cas9
switch and negativemiRNA inhibitor. The percentage of in-
sertions and deletions (indels) at the EGFP gene as assessed
by T7EI analysis showed similar trends as the flow cytom-
etry analysis (Supplementary Figure S4A versus Supple-
mentary Figure S5B), indicating that the loss of EGFP flu-
orescence intensity correlated with Cas9 nuclease activity.
Moreover, we performed DNA sequencing and observed
mutations at the target EGFP region in cells transfected
with control Cas9 mRNA and miR-302-Cas9 switch with
miR-302 inhibitor, but did not observe them with miR-302-
Cas9 switch and negative miRNA inhibitor (Supplemen-
tary Figure S6). These results confirm that miR-302-Cas9
switch repressed Cas9-mediated genome engineering by de-
tecting endogenousmiR-302 in hiPSCs. Thus, we selectively
controlled the activity of Cas9, in two different cell-types
(HeLa and hiPS cells) by using miR-21- and miR-302-Cas9
switches, respectively. In addition, these two switches had
negligible effect on endogenous mRNA expressions regu-
lated by miR-21 or miR-302 (Supplementary Figure S7).
The Cas9 activity in hiPSCs was slightly lower (∼30%)
than that in HeLa cells (∼50%), even though the sgRNA
and mRNA transfection efficiency was high in both cells
(∼90% efficiency for both cell types, Supplementary Figure
S8) (16). To further increase the Cas9 activity and miR-302
sensitivity in hiPSCs, we engineered sgRNA and miRNA-
responsive elements embedded in the 5′UTR of Cas9
mRNA (Supplementary Text). We redesigned sgRNAGFP
by removing the first tandem GG sequences (these do not
hybridize with the target EGFP sequence), in order to in-
crease the binding efficiency between the sgRNA and the
target sequence (26). To enhance the miRNA binding, we
inserted four tandem copies of anti-miR-302 sequences (in-
stead of one copy) in the 5′-UTR region of the switch (4×
miR-302-Cas9 switch). The resulting switch increased Cas9
activity (∼60%) and responded to endogenous miR-302
to modulate Cas9 production, because miR-302 inhibitor
recovered Cas9 activity (Figure 3). Thus, our miRNA-
responsive Cas9 switch could be fine-tuned the balance be-
tween Cas9 activity and miRNA sensitivity.
miR-302-Cas9 switch distinguishes hiPSCs and differenti-
ated neurons
The activities of miRNAs dynamically change during dif-
ferentiation. For example, miR-302 is highly expressed in
undifferentiated hiPSCs but repressed to basal level in mid-
brain dopaminergic (mDA) neuronal cells differentiated
from hiPSCs (16) (Supplementary Figure S1B, iPS versus
mDA).We expected thatmiR-302-Cas9 switch couldmodu-
late Cas9 activity before and after differentiation and cleave
a target gene in differentiated neurons but not in hiPSCs.
Therefore, we differentiated hiPSCs into mDA neurons (16)
and transfected the miR-302-Cas9 switch and sgRNA2GFP
into these cells. As expected, in contrast to the results from
hiPSCs, we observed Cas9 activity that was similar between
controlCas9mRNAandmiR-302-responsiveCas9mRNA
(Supplementary Figure S9).
Cell-type selective genome editing in mixed cell populations
Wenext investigatedwhethermiR-Cas9 switch could distin-
guish cells inmixed heterogeneous cell populations. Because
the translation from the miR-21- and miR-302-responsive
Cas9 mRNAs was selectively repressed in HeLa cells and
hiPSCs, respectively, we applied our system to distinguish
these two cell types. We mixed HeLa-EGFP and hiPS-
EGFP cells in a dish and aimed to knockout HeLa-EGFP
cells but not hiPS-EGFP cells, by employing the 4× miR-
302-Cas9 switch (Figure 4A). To distinguish the two cell
types, we stained the mixed cells with the TRA-1-60 an-
tibody (a cell surface marker specific to undifferentiated
pluripotent stem cells) for flow cytometry analysis. When
control (non-regulated) Cas9 mRNA was transfected into
the cell mixture, EGFP negative (knocked-out) cells were
observed in both HeLa cells and hiPSCs. In contrast, when
the 4×miR-302-Cas9 switch was transfected into themixed
cell population, the EGFP negative population was mainly
observed in HeLa cells but not in hiPSCs (Figure 4B–
D). This result showed that the miR-302-responsive Cas9
mRNA was preferentially translated to produce Cas9 in
HeLa cells compared with hiPSCs, facilitating the genome
editing activity in HeLa but preventing it in hiPSCs. Thus,
our miRNA-responsive Cas9 system distinguishes different
cell types within a heterogeneous cell population.
Nucleic Acids Research, 2017 7
Figure 3. Regulation of Cas9 activity in iPS cells by 4x miR-302-Cas9 switch and improved sgRNA. (A) Representative phase contrast and fluorescent
microscopic images at 72 h after RNA transfection. iPS-EGFP cells formed colonies (yellow dashed lines). Scale bar represents 200 m. (B) Representative
flow cytometry histograms of EGFP expression. x- and y-axes indicate EGFP intensity and % of max, respectively. (C) Quantification of Cas9 activity
from (B). A miR-302 inhibitor rescued Cas9 activity expressed from miR-302-responsive Cas9 mRNA, whereas a negative miRNA inhibitor did not. To
improve this system, 4x miR-302-responsive Cas9 mRNA (4 copies of miR-302 target site were tandemly inserted into 5′-UTR) and sgRNA2GFP (removal
of GG from 5′ terminal) were used. Negative control is Cas9–sgRNADMD that targets DMD gene. Error bars indicate the mean ± SD (n = 3).
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Figure 4. Cell-type-selective genome editing in a mixed cell population. (A) Schematic illustration of cell-type-selective gene knockout in a mixed cell
population. HeLa-EGFP and iPS-EGFP cells are mixed (HeLa/iPS co-culture), and 4× miR-302-responsive Cas9 mRNA is used. Because miR-302
activity is high in iPSCs, but not in HeLa cells, Cas9 protein is selectively produced in HeLa cells (low EGFP intensity). (B) Representative fluorescent
microscopic images at 72 h after RNA transfection. Phase contrast, EGFP and TRA-1-60 indicate phase contrast, EGFP fluorescent images and Alexa
Fluor 647 signal, respectively. Areas in the yellow dashed lines indicate TRA-1-60 positive hiPSCs. Scale bar represents 200 m. (C) Representative dot
plots. x- and y-axes indicate TRA-1-60 and EGFP, respectively. Q1 andQ4 indicateHeLa cells (TRA-1-60 negative). Q2 andQ3 indicate hiPSCs (TRA-1-60
positive). (D) EGFP knockout efficiencies of hiPSCs andHeLa cells in a co-culture condition. Bar graphs show EGFP negative populations. Gray and light
green boxes showHeLa and hiPSCs, respectively. 4×miR-302-responsiveCas9mRNAwas used for the experiments. Negative control is Cas9–sgRNADMD
that targets DMD gene. Error bars indicate the mean ± SD (n = 3).
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Figure 5. Construction of miR-Cas9-ON switch. (A) Mechanism of the ON system. The expressions of L7Ae from mRNA2 and Cas9 protein from
mRNA1 are suppressed by target miRNA (here, miR-21) and L7Ae, respectively. L7Ae suppresses the translation of Cas9 protein by interacting with its
binding motif (K-turn), and miR-21 suppresses the translation of L7Ae by interacting with its anti-sense region, resulting in Cas9 translation. (B) Flow
cytometry histograms of EGFP expression. The x- and y-axes indicate EGFP intensity and cell number, respectively. An increase of the EGFP negative
population was observed in miR-21-responsive L7AemRNA (ON) compared with control L7AemRNA (OFF). This experiment was repeated three times
and representative histograms are shown. Control L7Ae mRNA (L7Ae mRNA without miRNA-responsive element). Constitutive ON (without L7Ae
mRNA). (C) Quantification of relative Cas9 activity from (B). An increase of the EGFP negative population was observed in miR-21-responsive L7Ae
mRNA (ON) compared with control L7AemRNA (OFF). Each Cas9 activity was normalized by Constitutive ON (- L7Ae). Control L7AemRNA (L7Ae
mRNA without miRNA-responsive element). Constitutive ON (without L7Ae mRNA). Negative control is Cas9–sgRNADMD that targets DMD gene.
Error bars indicate the mean ± SD (n = 3).
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miR-Cas9-ON switch that enhancesCas9 production by sens-
ing target miRNA
Thus far, our miR-Cas9 switch system was able to achieve
potent Cas9 repression in target cells. In order to ad-
dress Cas9 activation in a cell-type specific manner, we
constructed a miR-Cas9-ON switch, which up-regulates
the translation of Cas9 mRNA by responding to a target
miRNA (Figure 5). We mimicked the topology of a cell-
classifier circuit that is composed of two mRNA species
(Cas9-coding mRNA1 and RNA-binding protein (L7Ae)-
coding mRNA2) (8). We designed the 5′-UTR sequence
of each mRNA to contain either the L7Ae-binding kink-
turn RNA motif (mRNA1) or the miR-21-responsive an-
tisense sequence (mRNA2). In the absence of the target
miRNA activity, L7Ae will be produced from mRNA2 and
repress the translation of Cas9 from mRNA1 through the
L7Ae-kink-turn RNA interaction. In contrast, in the pres-
ence of the target miRNA, L7Ae translation is repressed,
which in turn de-represses Cas9 translation (Figure 5A).
As designed, the co-transfection of both mRNAs and the
sgRNA increased the level of Cas9 activity by responding to
miR-21 in HeLa cells compared with untreated cells or cells
transfected with mRNA1 and control L7Ae mRNA with-
out miR-21-responsive element (Figure 5B, C). Thus, this
system can selectively increase the level of Cas9 activity in
target cells, by sensing the miRNA. Thus, both miR-Cas9-
OFF and miR-Cas9-ON switches can be constructed to de-
tect endogenousmiRNA signatures in mammalian cells, ex-
panding the possibilities for selective genome editing.
DISCUSSION
In this study, we developed a miRNA-responsive Cas9
switch system (miR-Cas9 switch) that is capable of perform-
ing cell-type selective genome editing by detecting an en-
dogenous miRNA signature, via a synthetic RNA delivery
approach. We can repress or activate Cas9 expression in
the presence or absence of the target miRNA, respectively,
by employing our miR-Cas9-OFF switch. Our method can
selectively control Cas9 activity that cleaved either an ex-
ogenous reporter gene (EGFP) integrated into the genome
or an endogenous repetitive genomic sequence (Alu1) by
detecting endogenous miRNA signatures: miR-21-5p and
miR-302a-5p in HeLa and hiPSCs, respectively (Figures 2
and 3). We also demonstrated the application of our miR-
Cas9 switch for the selective induction of genome editing in
HeLa cells within a mixed (hiPSCs and HeLa) cell popu-
lation (Figure 4). Additionally, by employing a cell classi-
fier circuit with an RNA-binding protein (L7Ae), we con-
structed a miR-Cas9-ON switch, which up-regulates Cas9
activity when the target miRNA is present in the cell (Fig-
ure 5).
We believe that our miR-Cas9 switch could provide a
promising framework to engineer genomes of target cells
for the following reasons: (1) RNA delivery approaches
are valuable for CRIPSR-Cas9 systems, as synthetic RNA
may avoid potentially harmful genomic integration (8). (2)
Our system can be used as a cell-type selective genome-
editing tool that responds to endogenous miRNA signa-
tures in target cells. Unlike non-cell autonomous regulation
systems (e.g. small chemicals or light), Cas9 activity is con-
trollable dependent on cell-state (miRNA activity). In fact,
we demonstrated cell-type-selective genome editing capabil-
ity in a heterogeneous cell population (Figure 4), although
further improvement of the performance of the OFF and
ON switches (e.g. avoiding translation of Cas9 protein from
kink-turn-Cas9 mRNA in the presence of L7Ae) is impor-
tant to reduce leaky expression of Cas9 in non-target cells.
This improvement could be achieved by employing switches
that detect multiple miRNAs (15). (3)MiRNAactivities dy-
namically change with development and cell reprograming.
Thus, by choosing an appropriate miRNA signature that
represents the target cell type or the cell state, we could se-
lectively control genome editing activity in a variety of cell
types. To reach this potential, it will be important to ex-
pand our knowledge about active and distinctive miRNA
signature(s) in different cell types (15). (4) Finally, our tech-
nology should be applicable to other Cas9 variants (e.g. or-
thologs, engineered Cas9/dCas9 proteins (27,28)) and other
miRNAs in a plug-and-play manner. Additionally, we be-
lieve that our miR-Cas9 switch could have important med-
ical applications. For example, we could maintain or pu-
rify target cells (e.g. iPS cells) but selectively eliminate non-
target cells by targeting repetitive elements (e.g. Alu1) us-
ing miR-Cas9 switch. Also, in order to develop a safe and
selective genome editing system in vivo, we may be able to
avoid unexpected off-target effects in non-target cells (e.g.
germ cells), by using germ cell-specific miRNA-responsive
switch. The transient and conditional expression of our sys-
tem using synthetic RNA could provide genome editing as a
potentially ‘one-shot therapy’ to treat numerous genetic dis-
eases. In conclusion, our miR-Cas9 switch combined with
a RNA-delivery approach can selectively engineer genomes
of target cells by detecting an endogenous miRNA signa-
ture, with potential benefits for synthetic biology, genome
editing field and future therapeutic applications.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
ACKNOWLEDGEMENTS
We thank Dr Hongmei Lisa Li (Kyoto University), Dr
Kanae Mitsunaga (Kyoto University) and Saito laboratory
members for kind advice about the experimental conditions,
data analysis and discussion. We also thank Dr Peter Kara-
giannis (Kyoto University) and Ms Yukiko Nakagawa &
Miho Nishimura for critical reading of the manuscript and
administrative support, respectively.
FUNDING
JSPS KAKENHI [15H05722, 24104002, 15H02376 to H.S.
and 15H05581 to A.H.]; Naito Foundation (to H.S.);
Canon Foundation (to H.S.); Nakatani Foundation (to
H.S.); JSPS Fellows [16J10715 to M.H.]. Funding for open
access charge: JSPS KAKENHI [15H05722 to H.S.].
Conflict of interest statement.Kyoto University has filed a
patent application broadly relevant to this work. M. Hiro-
sawa and H. Saito are the investigators of record listed on
the patent application.
Nucleic Acids Research, 2017 11
REFERENCES
1. Cong,L., Ran,F.A., Cox,D., Lin,S., Barretto,R., Habib,N., Hsu,P.D.,
Wu,X., Jiang,W., Marraffini,L.A. et al. (2013) Multiplex genome
engineering using CRISPR/Cas systems. Science, 339, 819–823.
2. Mali,P., Yang,L., Esvelt,K.M., Aach,J., Guell,M., DiCarlo,J.E.,
Norville,J.E. and Church,G.M. (2013) RNA-guided human genome
engineering via Cas9. Science, 339, 823–826.
3. Liang,X., Potter,J., Kumar,S., Zou,Y., Quintanilla,R., Sridharan,M.,
Carte,J., Chen,W., Roark,N., Ranganathan,S. et al. (2015) Rapid and
highly efficient mammalian cell engineering via Cas9 protein
transfection. J. Biotechnol., 208, 44–53.
4. Yin,H., Song,C.-Q., Dorkin,J.R., Zhu,L.J., Li,Y., Wu,Q., Park,A.,
Yang,J., Suresh,S., Bizhanova,A. et al. (2016) Therapeutic genome
editing by combined viral and non-viral delivery of CRISPR system
components in vivo. Nat. Biotechnol., 34, 328–333.
5. Nelson,C.E., Hakim,C.H., Ousterout,D.G., Thakore,P.I.,
Moreb,E.A., Rivera,R.M.C., Madhavan,S., Pan,X., Ran,F.A.,
Yan,W.X. et al. (2016) In vivo genome editing improves muscle
function in a mouse model of Duchenne muscular dystrophy. Science,
351, 403–407.
6. Thomas,C.E., Ehrhardt,A. and Kay,M.A. (2003) Progress and
problems with the use of viral vectors for gene therapy. Nat. Rev.
Genet., 4, 346–358.
7. Kim,S., Kim,D., Cho,S.W., Kim,J. and Kim,J.-S. (2014) Highly
efficient RNA-guided genome editing in human cells via delivery of
purified Cas9 ribonucleoproteins. Genome Res., 24, 1012–1019.
8. Wroblewska,L., Kitada,T., Endo,K., Siciliano,V., Stillo,B., Saito,H.
and Weiss,R. (2015) Mammalian synthetic circuits with RNA binding
proteins for RNA-only delivery. Nat. Biotechnol., 33, 839–841.
9. Hemphill,J., Borchardt,E.K., Brown,K., Asokan,A. and Deiters,A.
(2015) Optical Control of CRISPR/Cas9 Gene Editing. J. Am. Chem.
Soc., 137, 5642–5645.
10. Zetsche,B., Volz,S.E. and Zhang,F. (2015) A split-Cas9 architecture
for inducible genome editing and transcription modulation. Nat.
Biotechnol., 33, 139–142.
11. Liu,Y., Zhan,Y., Chen,Z., He,A., Li,J., Wu,H., Liu,L., Zhuang,C.,
Lin,J., Guo,X. et al. (2016) Directing cellular information flow via
CRISPR signal conductors. Nat. Methods, 13, 938–944.
12. Liu,Y., Zeng,Y., Liu,L., Zhuang,C., Fu,X., Huang,W. and Cai,Z.
(2014) Synthesizing AND gate genetic circuits based on
CRISPR–Cas9 for identification of bladder cancer cells. Nat.
Commun., 5, 5393.
13. Ma,D., Peng,S. and Xie,Z. (2016) Integration and exchange of split
dCas9 domains for transcriptional controls in mammalian cells. Nat.
Commun., 7, 13056.
14. Mullokandov,G., Baccarini,A., Ruzo,A., Jayaprakash,A.D., Tung,N.,
Israelow,B., Evans,M.J., Sachidanandam,R. and Brown,B.D. (2012)
High-throughput assessment of microRNA activity and function
using microRNA sensor and decoy libraries. Nat. Methods, 9,
840–846.
15. Miki,K., Endo,K., Takahashi,S., Funakoshi,S., Takei,I.,
Katayama,S., Toyoda,T., Kotaka,M., Takaki,T., Umeda,M. et al.
(2015) Efficient detection and purification of cell populations using
synthetic MicroRNA switches. Cell Stem Cell, 16, 699–711.
16. Parr,C.J.C., Katayama,S., Miki,K., Kuang,Y., Yoshida,Y.,
Morizane,A., Takahashi,J., Yamanaka,S. and Saito,H. (2016)
MicroRNA-302 switch to identify and eliminate undifferentiated
human pluripotent stem cells. Sci. Rep., 6, 32532.
17. Bassett,A.R., Tibbit,C., Ponting,C.P. and Liu,J.-L. (2013) Highly
efficient targeted mutagenesis of Drosophila with the CRISPR/Cas9
system. Cell Rep., 4, 220–228.
18. Warren,L., Manos,P.D., Ahfeldt,T., Loh,Y., Li,H., Lau,F., Ebina,W.,
Mandal,P.K., Smith,Z.D., Meissner,A. et al. (2010) Highly efficient
reprogramming to pluripotency and directed differentiation of human
cells with synthetic modified mRNA. Cell Stem Cell, 7, 618–630.
19. Oceguera-Yanez,F., Kim,S.-I., Matsumoto,T., Tan,G.W., Xiang,L.,
Hatani,T., Kondo,T., Ikeya,M., Yoshida,Y., Inoue,H. et al. (2016)
Engineering the AAVS1 locus for consistent and scalable transgene
expression in human iPSCs and their differentiated derivatives.
Methods, 101, 43–55.
20. Fu,Y., Foden,J.a, Khayter,C., Maeder,M.L., Reyon,D., Joung,J.K.
and Sander,J.D. (2013) High-frequency off-target mutagenesis
induced by CRISPR-Cas nucleases in human cells. Nat. Biotechnol.,
31, 822–826.
21. Feng,Y. and Tsao,C. (2016) Emerging role of microRNA-21 in cancer
(review). Biochem. Rep., 5, 395–402.
22. Xie,Z., Wroblewska,L., Prochazka,L., Weiss,R. and Benenson,Y.
(2011) Multi-Input RNAi-based logic circuit for identification of
specific cancer cells. Science, 333, 1307–1311.
23. Subramanyam,D., Lamouille,S., Judson,R.L., Liu,J.Y., Bucay,N.,
Derynck,R. and Blelloch,R. (2011) Multiple targets of miR-302 and
miR-372 promote reprogramming of human fibroblasts to induced
pluripotent stem cells. Nat. Biotechnol., 29, 443–448.
24. Li,H.L., Fujimoto,N., Sasakawa,N., Shirai,S., Ohkame,T.,
Sakuma,T., Tanaka,M., Amano,N., Watanabe,A., Sakurai,H. et al.
(2015) Precise correction of the dystrophin gene in duchenne
muscular dystrophy patient induced pluripotent stem cells by
TALEN and CRISPR–Cas9. Stem Cell Rep., 4, 143–154.
25. Cordaux,R. and Batzer,M.A. (2009) The impact of retrotransposons
on human genome evolution. Nat. Rev. Genet., 10, 691–703.
26. Cho,S.W., Kim,S., Kim,Y., Kweon,J., Kim,H.S., Bae,S. and Kim,J.-S.
(2014) Analysis of off-target effects of CRISPR/Cas-derived
RNA-guided endonucleases and nickases. Genome Res., 24, 132–141.
27. Kleinstiver,B.P., Prew,M.S., Tsai,S.Q., Topkar,V. V, Nguyen,N.T.,
Zheng,Z., Gonzales,A.P.W., Li,Z., Peterson,R.T., Yeh,J.-R.J. et al.
(2015) Engineered CRISPR–Cas9 nucleases with altered PAM
specificities. Nature, 523, 481–485.
28. Slaymaker,I.M., Gao,L., Zetsche,B., Scott,D.A., Yan,W.X. and
Zhang,F. (2016) Rationally engineered Cas9 nucleases with improved
specificity. Science, 351, 84–88.
